Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124151003 | 12415100 | 3 | F | 20160419 | 20160920 | 20160530 | 20160922 | EXP | FR-ROCHE-1765629 | ROCHE | 63.00 | YR | F | Y | 0.00000 | 20160922 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124151003 | 12415100 | 1 | PS | Cymevan | GANCICLOVIR | 1 | Intravenous drip | D | 19661 | 260 | MG | BID | |||||||
| 124151003 | 12415100 | 2 | SS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Unknown | D | 50722 | ||||||||||
| 124151003 | 12415100 | 3 | SS | LOXEN (FRANCE) | NICARDIPINE HYDROCHLORIDE | 1 | Oral | D | 0 | 50 | MG | BID | |||||||
| 124151003 | 12415100 | 4 | SS | LOXEN (FRANCE) | NICARDIPINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | LOXEN 5MG/5ML | D | 0 | |||||||||
| 124151003 | 12415100 | 5 | SS | SANDIMMUNE | CYCLOSPORINE | 1 | Intravenous drip | DOSAGE AT TIME OF THE FALL | D | 0 | 15 | MG | BID | ||||||
| 124151003 | 12415100 | 6 | SS | SANDIMMUNE | CYCLOSPORINE | 1 | Intravenous drip | D | 0 | 15 | MG | BID | |||||||
| 124151003 | 12415100 | 7 | SS | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous drip | D | 0 | 120 | MG | QD | |||||||
| 124151003 | 12415100 | 8 | C | FUNGIZONE | AMPHOTERICIN B | 1 | Oral | 0 | CAPSULE | ||||||||||
| 124151003 | 12415100 | 9 | C | CLAMOXYL (FRANCE) | AMOXICILLINCLAVULANIC ACID | 1 | Oral | 0 | CAPSULE | ||||||||||
| 124151003 | 12415100 | 10 | C | VFEND | VORICONAZOLE | 1 | Oral | 0 | TABLET | ||||||||||
| 124151003 | 12415100 | 11 | C | WELLVONE | ATOVAQUONE | 1 | Oral | 0 | |||||||||||
| 124151003 | 12415100 | 12 | C | LEVOTHYROX | LEVOTHYROXINE | 1 | Oral | 0 | 50 | UG | |||||||||
| 124151003 | 12415100 | 13 | C | SMECTA | MONTMORILLONITE | 1 | Oral | 0 | |||||||||||
| 124151003 | 12415100 | 14 | C | TIORFAN | RACECADOTRIL | 1 | Oral | 0 | |||||||||||
| 124151003 | 12415100 | 15 | C | CHOLURSO | URSODIOL | 1 | Oral | 0 | TABLET | ||||||||||
| 124151003 | 12415100 | 16 | C | VITABACT | PICLOXYDINE DIHYDROCHLORIDE | 1 | Ophthalmic | 0 | |||||||||||
| 124151003 | 12415100 | 17 | C | MIKICORT | BUDESONIDE | 1 | Oral | 0 | CAPSULE | ||||||||||
| 124151003 | 12415100 | 18 | C | NEORAL | CYCLOSPORINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124151003 | 12415100 | 1 | Cytomegalovirus infection |
| 124151003 | 12415100 | 2 | Prophylaxis against transplant rejection |
| 124151003 | 12415100 | 3 | Hypertension |
| 124151003 | 12415100 | 5 | Prophylaxis against transplant rejection |
| 124151003 | 12415100 | 7 | Acute graft versus host disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124151003 | 12415100 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124151003 | 12415100 | Fall |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124151003 | 12415100 | 1 | 20160331 | 20160427 | 0 | |
| 124151003 | 12415100 | 2 | 20160306 | 20160510 | 0 | |
| 124151003 | 12415100 | 3 | 20160414 | 20160528 | 0 | |
| 124151003 | 12415100 | 4 | 20160308 | 20160414 | 0 | |
| 124151003 | 12415100 | 5 | 20160306 | 20160420 | 0 | |
| 124151003 | 12415100 | 6 | 20160421 | 20160425 | 0 | |
| 124151003 | 12415100 | 7 | 20160326 | 20160413 | 0 |